Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput …
Over the last 12 months, insiders at Repligen Corporation have bought $600,476 and sold $14.08M worth of Repligen Corporation stock.
On average, over the past 5 years, insiders at Repligen Corporation have bought $316,041 and sold $21.15M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Madaus Martin D (director) — $605,328. BARTHELEMY NICOLAS (director) — $451,620. Hunt Anthony (Chief Executive Officer) — $248,160.
The last purchase of 1,615 shares for transaction amount of $201,776 was made by Madaus Martin D (director) on 2024‑06‑14.
2024-09-10 | Sale | director | 22,191 0.0393% | $145.37 | $3.23M | -4.57% | ||
2024-08-02 | Sale | Senior VP, R&D | 7,148 0.0126% | $159.35 | $1.14M | -10.47% | ||
2024-08-01 | Sale | Senior VP, R&D | 4,465 0.008% | $165.67 | $739,717 | -12.49% | ||
2024-06-14 | Chief Executive Officer | 2,000 0.0032% | $124.08 | $248,160 | +13.06% | |||
2024-06-14 | director | 1,200 0.0019% | $125.45 | $150,540 | +13.06% | |||
2024-06-14 | director | 1,615 0.0026% | $124.94 | $201,776 | +13.06% | |||
2024-05-21 | Sale | Chief Executive Officer | 20,072 0.0362% | $168.26 | $3.38M | -14.24% | ||
2024-03-11 | Sale | Senior VP, R&D | 3,517 0.0063% | $193.73 | $681,348 | -22.05% | ||
2024-03-08 | Sale | Chief Executive Officer | 16,707 0.0302% | $197.44 | $3.3M | -22.83% | ||
2024-02-27 | Sale | director | 1,000 0.0018% | $193.35 | $193,350 | -20.63% | ||
2024-02-23 | Sale | Chief Operating Officer | 4,373 0.0079% | $198.08 | $866,204 | -21.73% | ||
2023-11-10 | Sale | See Remarks | 3,788 0.0068% | $147.13 | $557,328 | +11.09% | ||
2023-08-29 | Sale | director | 850 0.0015% | $171.38 | $145,673 | -4.37% | ||
2023-05-08 | director | 500 0.0009% | $156.18 | $78,090 | +6.26% | |||
2023-05-05 | director | 500 0.0009% | $159.19 | $79,595 | +3.85% | |||
2023-05-04 | director | 500 0.0009% | $161.15 | $80,575 | +5.78% | |||
2023-02-16 | Sale | Chief Financial Officer | 5,647 0.0103% | $200.00 | $1.13M | -16.55% | ||
2022-11-11 | Sale | Chief Executive Officer | 25,000 0.0452% | $200.00 | $5M | -16.33% | ||
2022-09-09 | Sale | 775 0.0014% | $227.17 | $176,057 | -26.55% | |||
2022-09-08 | Sale | Chief Executive Officer | 6,626 0.0118% | $224.47 | $1.49M | -24.48% |
Hunt Anthony | director | 139840 0.2497% | $145.71 | 1 | 27 | |
DAWES KAREN A | director | 87367 0.156% | $145.71 | 5 | 21 | +21.46% |
BARTHELEMY NICOLAS | director | 4668 0.0083% | $145.71 | 1 | 7 | |
Madaus Martin D | director | 4613 0.0082% | $145.71 | 4 | 0 | +5.3% |
HERLIHY WALTER C | PRESIDENT, CEO | 262430 0.4686% | $145.71 | 1 | 15 | +58.42% |
BlackRock | $1.43B | 13.91 | 7.77M | -1.1% | -$15.91M | 0.03 | |
The Vanguard Group | $937.99M | 9.13 | 5.1M | +0.43% | +$3.99M | 0.02 | |
T. Rowe Price | $656.29M | 6.39 | 3.57M | -11.02% | -$81.28M | 0.08 | |
Fidelity Investments | $415.25M | 4.04 | 2.26M | +19.93% | +$69.02M | 0.03 | |
State Street | $323.37M | 3.15 | 1.76M | +3.21% | +$10.04M | 0.01 |